Publications by authors named "K Wittstock"
Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis.
J Comp Eff Res
December 2024
Article Synopsis
- In rheumatoid arthritis, having both anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF) indicates more severe disease and can affect treatment outcomes; abatacept is a recommended biologic treatment for those who don't respond to traditional medications.
- A study tracking 296 RA patients treated with abatacept showed significant improvement in clinical disease activity over 12 months, with mean disease activity scores decreasing by up to 74% after treatment.
- Among patients who initially had high disease activity, about 71% achieved low disease activity or remission during the follow-up, and serious adverse events were reported in only 2.4% of cases, highlighting abatacept's effectiveness and safety.
Background: Understanding the economic value of deucravacitinib and apremilast could assist treatment decision-making for patients with moderate to severe plaque psoriasis.
Objective: This study compared the cost per response (CPR) for US patients initiating deucravacitinib versus apremilast for moderate to severe plaque psoriasis.
Methods: A CPR model using pharmacy and administration costs was developed from a US payer perspective.
Purpose: Providers who treat patients with psoriasis are unevenly distributed across the United States, with more in urban than rural areas. This retrospective claims analysis characterized disparities in access to care for US patients with psoriasis using data from the STATinMED database.
Materials And Methods: Patients (≥18 years) had ≥1 claim with a psoriasis diagnosis and ≥1 claim for advanced psoriasis therapy (apremilast or biologics) between January 2015 and December 2019.
To examine racial/ethnic differences in rheumatoid arthritis (RA) disease burden and change in clinical outcomes over time. We included CorEvitas Rheumatoid Arthritis Registry patients from two time periods (2013-2015 and 2018-2020). Clinical Disease Activity Index (CDAI) (as a continuous measure and as a dichotomous measure) and the Health Assessment Questionnaire-Disability Index (HAQ-DI) were assessed at each visit.
View Article and Find Full Text PDFBackground: The HLA-DRB1 shared epitope (SE) is a risk factor for the development of rheumatoid arthritis (RA) and the production of anti-citrullinated protein antibodies (ACPAs) in RA patients. Our objective was to examine the real-world effectiveness of abatacept versus tumor necrosis factor inhibitors (TNFi) in patients with RA who were SE and anti-cyclic citrullinated peptide antibody (anti-CCP3) positive.
Methods: Abatacept or TNFi initiators who were SE + and anti-CCP3+ (> 20 U/mL) at or prior to treatment and had moderate or high CDAI score (> 10) at initiation were identified.